

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

VANCOUVER, BC, Nov. 18, 2021 /CNW/ -- **BioVaxys Technology Corp.** (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("**BioVaxys**" or "**Company**"), a clinical-stage immunotherapy company, is pleased to announce that its Chief Medical Officer David Berd, MD, has been invited by the Editorial Board of *Therapeutic Advances in Vaccines and Immunotherapy* to submit a scientific review article based on his speaking engagement entitled "Haptenized Protein Vaccines for Viral Diseases and Cancer" on December 1st at the World Vaccine & Immunotherapy Congress ("WVIC") in San Diego, CA.

Therapeutic Advances in Vaccines and Immunotherapy is a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions. It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC.

Scientific conferences and journal articles are critical for an open sharing of ideas and research results, and provide a way to attract scientific interest, research collaborations, and commercial interest. "We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys. "As we have now significantly built our patent portfolio, we are in a better position to share our technologies more broadly within scientific community as we look for Principal Investigators for our upcoming clinical studies, and potential development partners."

About BioVaxys Technology Corp.

Based in Vancouver, [BioVaxys Technology Corp.](http://www.biovaxys.com) (www.biovaxys.com) is a British Columbia-registered, clinical-stage immunotherapy company developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: [BVAXF](http://www.biovaxys.com)).

ON BEHALF OF THE BOARD

Signed "James Passin"
James Passin, CEO
+1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

*This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. **There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.** These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.*

Media Contact:

Gina Cestari
6 Degrees Public Relations
gcestari@6degreespr.com
+1 917 797 7904

View original content to download multimedia:
<https://www.prnewswire.com/news-releases/biovaxys-chief-medical-officer-david-berd-md-invited-by-editorial-board-of-therapeutic-advances-in-vaccines-and-immu>

SOURCE BioVaxys Technology Corp.

View original content to download multimedia: <http://www.newswire.ca/en/releases/archive/November2021/18/c6574.html>

%SEDAR: 00045617E

CO: BioVaxys Technology Corp.

CNW 08:41e 18-NOV-21